The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Ascorbic acid in Charcot–Marie–Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial
Open accessAbstract
BACKGROUND: Ascorbic acid reduced the severity of neuropathy in transgenic mice overexpressing peripheral myelin protein 22 (PMP22), a model of Charcot-Marie-Tooth disease type 1A (CMT1A) associated with the PMP22 duplication. However, in three 1-year trials, ascorbic acid had no benefit in human beings. We did a multicentre 2-year trial to test the efficacy and tolerability of ascorbic acid in patients with CMT1A. METHODS: Adult patients (aged 18-70 years) with symptomatic CMT1A were enrolled from nine centres in Italy and the UK, and were randomly assigned (1:1 ratio) to receive 1·5 g/day oral ascorbic acid or matching placebo for 24 months. The randomisation sequence was computer generated by block randomisation, stratified by centre and disease severity, and patients were allocated to treatment by telephone. The primary outcome was change in the CMT neuropathy score (CMTNS) at 24 months. Secondary outcomes were timed 10 m walk test, nine-hole peg test, overall neuropathy limitations scale, distal maximal voluntary isometric contraction, visual analogue scales for pain and fatigue, 36-item short-form questionnaire, and electrophysiological measurements. Patients, treating physicians, and physicians assessing outcome measures were masked to treatment allocation. Analysis of the primary outcome was done on all randomised patients who received at least one dose of study drug. This study is registered, numbers ISRCTN61074476 (CMT-TRAUK) and EudraCT 2006-000032-27 (CMT-TRIAAL). FINDINGS: We enrolled and randomly assigned 277 patients, of whom six (four assigned to receive ascorbic acid) withdrew consent before receiving treatment; 138 receiving ascorbic acid and 133 receiving placebo were eligible for analysis. Treatment was well tolerated: 241 of 271 patients (89% in each group) completed the study; 20 patients (nine receiving ascorbic acid) dropped out because of adverse events. Mean CMTNS at baseline with missing data imputed was 14·7 (SD 4·8) in the ascorbic acid group and 13·9 (4·2) in the placebo group. Mean worsening of CMTNS was 0·2 (SD 2·8, 95% CI -0·3 to 0·7) in the ascorbic acid group and 0·2 (2·7, -0·2 to 0·7) in the placebo group (mean difference 0·0, 95% CI -0·6 to 0·7; p=0·93). We recorded no differences between the groups for the secondary outcomes at 24 months. 21 serious adverse events occurred in 20 patients, eight in the ascorbic acid group and 13 in the placebo group. INTERPRETATION: Ascorbic acid supplementation had no significant effect on neuropathy compared with placebo after 2 years, suggesting that no evidence is available to support treatment with ascorbic acid in adults with CMT1A. FUNDING: Telethon-UILDM and AIFA (Italian Medicines Agency) for CMT-TRIAAL, and Muscular Dystrophy Campaign for CMT-TRAUK.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1992) · PubMed · Cited by 33,716
The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection
Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033
Assessment of chronic pain. I. Aspects of the reliability and validity of the visual analogue scale
Carlsson, A. M. (1983) · Pain · doi:10.1016/0304-3959(83)90088-x · Cited by 1,853
Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance
Levine, M., Conry-Cantilena, C., Wang, Y., Welch, R. W., Washko, P. W., Dhariwal, K. R., Park, J. B., Lazarev, A., Graumlich, J. F., King, J., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.8.3704 · Cited by 1,325
The Italian SF-36 Health Survey
Apolone, G., & Mosconi, P. (1998) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(98)00094-8 · Cited by 1,148
Diagnosis, natural history, and management of Charcot–Marie–Tooth disease
Pareyson, D., & Marchesi, C. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70110-3 · Cited by 621
Self-citationA modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale
Graham, R. C. (2006) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2005.081547 · Cited by 405
BRADLEY, L. A., PROKOP, C. K., GENTRY, W. D., VAN DER HEIDE, L. H., & PRIETO, E. J. (1981) · Medical Psychology · doi:10.1016/b978-0-12-565960-4.50012-6 · Cited by 384
Reliability and validity of the CMT neuropathy score as a measure of disability
Shy, M. E., Blake, J., Krajewski, K., Fuerst, D. R., Laura, M., Hahn, A. F., Li, J., Lewis, R. A., & Reilly, M. (2005) · Neurology · doi:10.1212/01.wnl.0000156517.00615.a3 · Cited by 357
Self-citationAscorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease
Passage, E., Norreel, J. C., Noack-Fraissignes, P., Sanguedolce, V., Pizant, J., Thirion, X., Robaglia-Schlupp, A., Pellissier, J. F., & Fontés, M. (2004) · Nature Medicine · doi:10.1038/nm1023 · Cited by 349
Cited by
Clinical implications of genetic advances in Charcot–Marie–Tooth disease
Rossor, A. M., Polke, J. M., Houlden, H., & Reilly, M. M. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.179 · Cited by 358
Self-citationFridman, V, Bundy, B., Reilly, M. M., Pareyson, D., Bacon, C., Burns, J., Day, J., Feely, S., Finkel, R. S., Grider, T., et al. (2015) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-308826 · Cited by 354
Self-citationMorrow, J. M., Sinclair, C. D. J., Fischmann, A., Machado, P. M., Reilly, M. M., Yousry, T. A., Thornton, J. S., & Hanna, M. G. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00242-2 · Cited by 342
Self-citationRegulation of the epigenome by vitamin C
Young, J. I., Züchner, S., & Wang, G. (2015) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071714-034228 · Cited by 319
Distal Symmetric Polyneuropathy: A Review
Callaghan, B. C., Price, R. S., & Feldman, E. L. (2015) · JAMA · doi:10.1001/jama.2015.13611 · Cited by 289
Metadata
- Authors
- Pareyson, D., Reilly, M. M., Schenone, A., Fabrizi, G. M., Cavallaro, T., Santoro, L., Vita, G., Quattrone, A., Padua, L., Gemignani, F., Visioli, F., Laurà, M., Radice, D., Calabrese, D., Hughes, R. A., & Solari, A.
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2011-04
- Volume
- 10
- Issue
- 4
- Pages
- 320-328
- ISSN
- 1474-4422 (ISSN-L)
- OpenAlex
- W2102244428
- Cited by
- 267
- References
- 23
- FWCI
- 10.36
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ascorbic acid in Charcot–Marie–Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial. https://app.cochat.ai/papers/10.1016/s1474-4422(11)70025-4
- The paper
- Pareyson, D., Reilly, M. M., Schenone, A., Fabrizi, G. M., Cavallaro, T., Santoro, L., Vita, G., Quattrone, A., Padua, L., Gemignani, F., Visioli, F., Laurà, M., Radice, D., Calabrese, D., Hughes, R. A., & Solari, A. (2011). Ascorbic acid in Charcot–Marie–Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(11)70025-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.